Stem Cell Maintenance and Disease Progression in Chronic Myeloid Leukemia

Overview

Journal Int J Hematol

Specialty Hematology

Date 2013 Apr 4

PMID 23550022

Citations 9

Authors

Takahiro Ito

Affiliations

Soon will be listed here.

Abstract

Chronic myeloid leukemia (CML) is a cancer of blood cells driven by the BCR-ABL1 oncogenic protein tyrosine kinase, which is the product of a reciprocal chromosomal translocation known as the Philadelphia chromosome. Discovery of tyrosine kinase inhibitors targeting the BCR-ABL1 kinase revolutionized CML therapy, but these drugs are unable to eradicate the disease due to the presence of a drug-insensitive stem cell population that sustains continued growth of the malignant cells. Resistance to therapies also increases the risk of relapse and disease progression to a more advanced phase. This review discusses emerging issues in CML research, and describes recent progress in elucidating the mechanisms of CML stem cell maintenance and disease progression.

Citing Articles

Persistent detection of alternatively spliced BCR-ABL variant results in a failure to achieve deep molecular response.

Yuda J, Miyamoto T, Odawara J, Ohkawa Y, Semba Y, Hayashi M Cancer Sci. 2017; 108(11):2204-2212.

PMID: 28801986 PMC: 5666036. DOI: 10.1111/cas.13353.

Dynamical models of mutated chronic myelogenous leukemia cells for a post-imatinib treatment scenario: Response to dasatinib or nilotinib therapy.

Woywod C, Gruber F, Engh R, Fla T PLoS One. 2017; 12(7):e0179700.

PMID: 28678800 PMC: 5497988. DOI: 10.1371/journal.pone.0179700.

The human Smoothened inhibitor PF-04449913 induces exit from quiescence and loss of multipotent Drosophila hematopoietic progenitor cells.

Giordani G, Barraco M, Giangrande A, Martinelli G, Guadagnuolo V, Simonetti G Oncotarget. 2016; 7(34):55313-55327.

PMID: 27486815 PMC: 5342419. DOI: 10.18632/oncotarget.10879.

Chronic myelogenous leukemia in chronic phase transforming into acute leukemia under treatment with dasatinib 4 months after diagnosis.

Nakamura Y, Tokita K, Nagasawa F, Takahashi W, Nakamura Y, Sasaki K Int J Hematol. 2015; 103(3):348-53.

PMID: 26662559 DOI: 10.1007/s12185-015-1909-7.

Small RNA as a regulator of hematopoietic development, immune response in infection and tumorigenesis.

Okuyama K, Ogata J, Yamakawa N, Chanda B, Kotani A Int J Hematol. 2014; 99(5):553-60.

PMID: 24687917 DOI: 10.1007/s12185-014-1564-4.

References

Jordan C, Guzman M, Noble M . Cancer stem cells. N Engl J Med. 2006; 355(12):1253-61. DOI: 10.1056/NEJMra061808. View

Mayotte N, Roy D, Yao J, Kroon E, Sauvageau G . Oncogenic interaction between BCR-ABL and NUP98-HOXA9 demonstrated by the use of an in vitro purging culture system. Blood. 2002; 100(12):4177-84. DOI: 10.1182/blood-2002-04-1244. View

Zhao C, Blum J, Chen A, Kwon H, Jung S, Cook J . Loss of beta-catenin impairs the renewal of normal and CML stem cells in vivo. Cancer Cell. 2007; 12(6):528-41. PMC: 2262869. DOI: 10.1016/j.ccr.2007.11.003. View

Ishikawa F, Yoshida S, Saito Y, Hijikata A, Kitamura H, Tanaka S . Chemotherapy-resistant human AML stem cells home to and engraft within the bone-marrow endosteal region. Nat Biotechnol. 2007; 25(11):1315-21. DOI: 10.1038/nbt1350. View

Huettner C, Koschmieder S, Iwasaki H, Iwasaki-Arai J, Radomska H, Akashi K . Inducible expression of BCR/ABL using human CD34 regulatory elements results in a megakaryocytic myeloproliferative syndrome. Blood. 2003; 102(9):3363-70. DOI: 10.1182/blood-2003-03-0768. View

Graham S, Jorgensen H, Allan E, Pearson C, Alcorn M, Richmond L . Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro. Blood. 2002; 99(1):319-25. DOI: 10.1182/blood.v99.1.319. View

Aikawa Y, Katsumoto T, Zhang P, Shima H, Shino M, Terui K . PU.1-mediated upregulation of CSF1R is crucial for leukemia stem cell potential induced by MOZ-TIF2. Nat Med. 2010; 16(5):580-5, 1p following 585. PMC: 3039870. DOI: 10.1038/nm.2122. View

Perrotti D, Jamieson C, Goldman J, Skorski T . Chronic myeloid leukemia: mechanisms of blastic transformation. J Clin Invest. 2010; 120(7):2254-64. PMC: 2898591. DOI: 10.1172/JCI41246. View

Bao S, Wu Q, McLendon R, Hao Y, Shi Q, Hjelmeland A . Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature. 2006; 444(7120):756-60. DOI: 10.1038/nature05236. View

10.

Viswanathan S, Powers J, Einhorn W, Hoshida Y, Ng T, Toffanin S . Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009; 41(7):843-8. PMC: 2757943. DOI: 10.1038/ng.392. View

11.

Thomson J, Newman M, Parker J, Morin-Kensicki E, Wright T, Hammond S . Extensive post-transcriptional regulation of microRNAs and its implications for cancer. Genes Dev. 2006; 20(16):2202-7. PMC: 1553203. DOI: 10.1101/gad.1444406. View

12.

Koschmieder S, Gottgens B, Zhang P, Iwasaki-Arai J, Akashi K, Kutok J . Inducible chronic phase of myeloid leukemia with expansion of hematopoietic stem cells in a transgenic model of BCR-ABL leukemogenesis. Blood. 2004; 105(1):324-34. DOI: 10.1182/blood-2003-12-4369. View

13.

Pear W, Miller J, Xu L, Pui J, Soffer B, Quackenbush R . Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood. 1998; 92(10):3780-92. View

14.

Naka K, Hoshii T, Muraguchi T, Tadokoro Y, Ooshio T, Kondo Y . TGF-beta-FOXO signalling maintains leukaemia-initiating cells in chronic myeloid leukaemia. Nature. 2010; 463(7281):676-80. DOI: 10.1038/nature08734. View

15.

Dierks C, Beigi R, Guo G, Zirlik K, Stegert M, Manley P . Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation. Cancer Cell. 2008; 14(3):238-49. DOI: 10.1016/j.ccr.2008.08.003. View

16.

Druker B . Translation of the Philadelphia chromosome into therapy for CML. Blood. 2008; 112(13):4808-17. DOI: 10.1182/blood-2008-07-077958. View

17.

Melo J, Barnes D . Chronic myeloid leukaemia as a model of disease evolution in human cancer. Nat Rev Cancer. 2007; 7(6):441-53. DOI: 10.1038/nrc2147. View

18.

Corbin A, Agarwal A, Loriaux M, Cortes J, Deininger M, Druker B . Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity. J Clin Invest. 2010; 121(1):396-409. PMC: 3007128. DOI: 10.1172/JCI35721. View

19.

Deininger M . Stem cell persistence in chronic myeloid leukemia. Leuk Suppl. 2016; 1(Suppl 2):S46-8. PMC: 4851205. DOI: 10.1038/leusup.2012.24. View

20.

Deininger M, Buchdunger E, Druker B . The development of imatinib as a therapeutic agent for chronic myeloid leukemia. Blood. 2004; 105(7):2640-53. DOI: 10.1182/blood-2004-08-3097. View